哈药股份：获乳酸钙原料药上市申请批准

Core Viewpoint - The approval of calcium lactate by the National Medical Products Administration marks a significant advancement for the company in the active pharmaceutical ingredient sector, enhancing its product portfolio and enabling greater control over its raw materials [1] Group 1: Regulatory Approval - The company’s subsidiary, Harbin Pharmaceutical Group Sanjing Ming Water Pharmaceutical Co., Ltd., received the approval notice for calcium lactate as a chemical raw material drug [1] - Calcium lactate is primarily used as a calcium supplement in pharmaceutical formulations, and the raw material has met the national drug review technical standards [1] Group 2: Investment and Development - The company has invested approximately 6.5789 million yuan in the research and development of the calcium lactate raw material project [1] - This approval is a crucial step in the company's strategy to achieve self-sufficiency in raw materials and diversify its product offerings [1]